Elsevier

Biochemical Pharmacology

Volume 47, Issue 4, 11 February 1994, Pages 737-741
Biochemical Pharmacology

Short communication
Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acid

https://doi.org/10.1016/0006-2952(94)90137-6Get rights and content

Abstract

The metabolism of 4-keto-all-trans-retinoic-acid (4-keto-RA), a biologically active oxygenated metabolite of all-trans-retinoic (RA), has been examined. In vitro, incubation of [14C]4-keto-RA with hamster liver microsomes in the presence of NADPH produced two major radioactive metabolites which were more polar than the parent compound. Following isolation, appropriate derivatization and analysis by GC-MS, these compounds were tentatively identified as 2-hydroxy- and 3-hydroxy-4-ketoretinoic acid. Formation of both hydroxy-keto derivatives was suppressed by the imidazole-containing P450 inhibitor liarozole fumarate (ic50, 1.3μM). In vivo, an i.V. injection of 4-keto-RA (20 μg) into rats was followed by rapid disappearance of the retinoid from plasma with a half-life of 7 min. Pretreatment with liarozole fumarate (40 mg/kg, -60 min) reduced the elimination rate of 4-keto-RA: it prolonged the plasma half-life of the retinoid to 12 min, without affecting its distribution volume. These results indicate the important role of the P450 enzyme system in the metabolism of 4-keto-RA both in vitro and in vivo. The inhibitory effect of liarozole fumarate on this metabolic process may contribute to the reported retinoid-mimetic activity of this drug.

References (26)

  • JC Kraft et al.

    Plasma pharmacokinetics and metabolism of β-cis-and all-trans-retinoic acid in the cynomolgus monkey and the identification of β-cis-and all-trans-retinoyl-β-glucuronides

    Drug Metab Dispos

    (1991)
  • JB Williams et al.

    Inhibition of retinoic acid metabolism by imidazole antimycotics in F9 embryonal carcinoma cells

  • JP Van Wauwe et al.

    Ketoconazole inhibits the in viitro and in vivo metabolism of all-trans-retinoic acid

    J Pharmacol Exp Ther

    (1988)
  • Cited by (0)

    View full text